Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Managing toxicities with asparaginase-based therapies in adult all: Summary of an ESMO Open-Cancer Horizons roundtable discussion
    Review

    Burke, P. W.; Hoelzer, D.; Park, J. H.; Schmiegelow, K.; Douer, D.
    ESMO Open (2020)

    Fulltext@MSK | Save
  • TGFβR-SMAD3 signaling induces resistance to PARP inhibitors in the bone marrow microenvironment
    Journal Article

    Le, B. V.; Podszywalow-Bartnicka, P.; Maifrede, S.; Sullivan-Reed, K.; Nieborowska-Skorska, M.; Golovine, K.; Yao, J. C.; Nejati, R.; Cai, K. Q.; Caruso, L. B.; more...
    Cell Reports (2020)

    Fulltext@MSK | Save
  • Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms
    Journal Article

    Taylor, J.; Mi, X.; North, K.; Binder, M.; Penson, A.; Lasho, T.; Knorr, K.; Haddadin, M.; Liu, B.; Pangallo, J.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: A SEER-Medicare analysis
    Meeting Abstract

    Stein, E.; Latremouille-Viau, D.; Shi, S.; Guerin, A.; Wu, E.; Bonifacio, G.; Cao, X.
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • A SEER-Medicare analysis of treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agent
    Meeting Abstract

    Stein, E.; Latremouille-Viau, D.; Shi, S.; Guerin, A.; Wu, E.; Bonifacio, G.; Cao, X.
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Ivosidenib (IVO) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment of a phase 1 dose escalation and expansion study
    Meeting Abstract

    DiNardo, C. D.; Foran, J. M.; Watts, J. M.; Stein, E. M.; de Botton, S.; Fathi, A. T.; Prince, G. T.; Stein, A. S.; Stone, R. M.; Patel, P. A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Interim analysis from the OPTIC trial - A dose-ranging study of 3 starting doses of ponatinib
    Meeting Abstract

    Cortes, J.; Lomaia, E.; Turkina, A.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Rojas, C.; Chuah, C.; Arthur, C.; Apperley, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Efficacy and safety of asciminib in heavily pretreated patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) with sensitivity to tyrosine kinase inhibitors (TKIs)
    Meeting Abstract

    Hughes, T.; Mauro, M.; Kim, D. W.; Cortes, J.; Réa, D.; Minami, H.; Breccia, M.; DeAngelo, D.; Hochhaus, A.; Goh, Y. T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Incidence of cardiovascular (CV)-related hospitalizations and associated costs among US patients with chronic-phase chronic myeloid leukemia (CP-CML) treated with first-line (1L) tyrosine kinase inhibitors (TKI) in SIMPLICITY: An observational study
    Meeting Abstract

    Goldberg, S. L.; Mauro, M.; Cortes, J.; Keating, S. J.; Bhandari, H.; Chen, C.
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Ivosidenib (IVO) prior to hematopoietic cell transplant (HCT) for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML) who cannot tolerate intensive chemotherapy (IC)
    Meeting Abstract

    DiNardo, C. D.; Stein, E. M.; Pigneux, A.; Altman, J. K.; Collins, R.; Erba, H. P.; Watts, J. M.; Uy, G. L.; Wu, B.; Choe, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save